Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Teva Takeda Pharma

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

Lannett appoints Teva’s Michael Bogda as president

He served as VP of technical operations in for Teva’s Americas division

- PMLiVE

UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat

- PMLiVE

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost

- PMLiVE

Merck files once-weekly DPP-4 inhibitor in first market

Picks Japan to submit omarigliptin

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

Takeda enlists GE’s aid to tackle liver fibrosis epidemic

Non-alcoholic liver disease has doubled in the last 20 years

- PMLiVE

Takeda launches mobile app for heartburn patients

Food4GERD app includes symptom tracker and ingredient check functions

Teva Pharma logo

Cuts help Teva raise profits, despite flat sales

Earnings attributed largely to firm’s generics business

- PMLiVE

US judge cuts billions from Takeda/Lilly Actos payment

Court rules that companies must now pay damages of $36.8m rather than $9bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links